Predictors of drug survival of biologic therapies in psoriasis patients

Zorlu O., BÜLBÜL BAŞKAN E., YAZİCİ S., SIĞIRLI D., BUDAK F., SARICAOĞLU H., ...Daha Fazla

JOURNAL OF DERMATOLOGICAL TREATMENT, cilt.33, sa.1, ss.437-442, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1080/09546634.2020.1763240
  • Dergi Adı: JOURNAL OF DERMATOLOGICAL TREATMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.437-442
  • Anahtar Kelimeler: Anti-TNF, biologics, HLA-Cw6, psoriasis, CLINICAL-RESPONSE, OBSERVATIONAL COHORT, BRITISH ASSOCIATION, USTEKINUMAB, POLYMORPHISMS, ETANERCEPT, ADALIMUMAB, HLA-C-ASTERISK-06, ANTIBODIES, ALLELE
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Introduction: We aimed to investigate the clinical, immunological, and genetic factors affecting the response to anti-TNF alpha (tumor necrosis factor-alpha) and interleukin-12/23 therapies and drug survivals. Methods: A total of 180 patients were divided into two groups: 89 patients who used at least two biologic agents, with the initial biologic agent used less than 12 months (group A), and 91 biologic-naive patients who have been receiving a single biologic agent for more than 12 months (group B). ELISA (enzyme-linked immunosorbent assay) was used to analyze anti-drug antibodies (ADAs) in blood samples. Clinical data of the patients were retrospectively analyzed. HLA-SSO (sequence-specific oligonucleotide) Typing Kits were used for HLA-C typing. IBM SPSS v.21 was used for statistical analysis. Results: Infliximab had the longest drug survival as the first biologic agent in group A (p = .015). Etanercept had the lowest ADA count compared to the other anti-TNF agents (p = .001). HLA-Cw6 negativity, late-onset psoriasis, smoking and alcohol use were determined to be risk factors for treatment failure in group A. HLA-Cw6 was found to be associated with type I psoriasis (p = .000). Conclusions: Although our study is retrospective of a relatively low number of patients, this is a preliminary study focusing on two different patient populations based on therapy response.